CD19 and precursor B-cell acute lymphoblastic leukemia: Obecabtagene autoleucel (or obe-cel) is a CD19-directed CAR T-cell therapy indicated in the treatment of adults with refractory B-cell precursor acute lymphoblastic leukemia.